BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Rhea-AI Summary

BioAge (Nasdaq: BIOA) will host an R&D Day webcast on May 8, 2026 from 12:30–2:00 PM ET focused on BGE-102, an orally available NLRP3 inflammasome inhibitor. Management will present Phase 1 clinical data and the therapeutic rationale for ASCVD and retinal disease.

Four academic and clinical experts will join presentations and a live Q&A. A recording will be available in the company's Events section at the investor relations website.

News Market Reaction – BIOA

+0.36%

1 alert

+0.36% Session close to close

$740.56M Market Cap

0.0x Rel. Volume

In the May 5 session, BIOA gained 0.36%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules an R&D Day on May 8, 2026 to showcase Phase 1 data for BGE-102 and the r...

Analysis

This announcement schedules an R&D Day on May 8, 2026 to showcase Phase 1 data for BGE-102 and the rationale for targeting NLRP3 in cardiometabolic and retinal diseases. It follows earlier positive BGE-102 data and recent corporate filings that strengthened BIOA’s balance sheet and financing flexibility. Investors may watch for new details on efficacy, safety, and trial plans, alongside how management frames the program’s role within the broader pipeline and existing Form S-3ASR capacity.

Key Figures

Event date: May 8, 2026 Webcast time: 12:30–2:00 PM ET Expert speakers: 4 experts

3 metrics

Event date May 8, 2026 Scheduled R&D Day focused on NLRP3 inhibition

Webcast time 12:30–2:00 PM ET Duration of R&D Day webcast

Expert speakers 4 experts Academic and clinical experts joining BioAge management

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 21	Annual report release	Positive	+4.3%	Annual and sustainability reports highlighting breakthrough Alzheimer’s drug and record profits.
Apr 21	Clinical data update	Positive	+4.3%	Positive Phase 1 BGE-102 data showing large hsCRP reductions and good tolerability.
Apr 13	Conference presentation	Neutral	+2.4%	Participation in Needham healthcare conference with webcasted fireside chat and meetings.
Mar 27	Board nominations	Neutral	-0.6%	Nomination committee proposals for board composition and chairperson at AGM.
Mar 24	Earnings and financing	Negative	-13.5%	Full-year 2025 results with net loss and disclosure of a $132.3M upsized follow-on offering.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Price reactions generally align with news tone, with positive clinical and corporate updates followed by gains and a negative earnings/financing update followed by a decline.

Recent Company History

Over recent months, BIOA and related entities reported several notable events. An annual report highlighted a breakthrough Alzheimer’s drug and record-high profits on Apr 21, 2026, with shares rising afterward. BIOA’s own positive Phase 1 BGE-102 data on Apr 21, 2026 also preceded a gain. A Needham conference appearance on Apr 13, 2026 saw a modest uptick. In contrast, full-year 2025 results and an upsized $132.3M follow-on offering on Mar 24, 2026 coincided with a double‑digit decline, underscoring sensitivity to financing and loss metrics.

Key Terms

nlrp3 inflammasome, atherosclerotic cardiovascular disease, ascvd, diabetic macular edema, +1 more

5 terms

nlrp3 inflammasome medical

"the Company's potent, structurally novel, orally available NLRP3 inflammasome inhibitor with potential best-in-class attributes"

A protein complex inside immune cells that acts like a cellular smoke alarm: it senses stress or danger signals and triggers a rapid inflammatory response by activating enzymes that release inflammatory molecules. Investors pay attention because blocking or modulating this pathway is a major drug-development target for a range of diseases (inflammatory, cardiovascular, metabolic, neurodegenerative), so progress, trial results, safety signals, or regulatory decisions around NLRP3-targeting therapies can materially affect clinical prospects, market size, and company valuation.

atherosclerotic cardiovascular disease medical

"for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease"

Atherosclerotic cardiovascular disease is the chronic narrowing and hardening of arteries caused by buildup of fatty plaques, like pipes gradually clogged by residue, which reduces blood flow to the heart, brain and other organs. It matters to investors because it is a leading driver of demand for drugs, medical devices, diagnostics and long‑term care—and outcomes from clinical trials, approvals or changes in treatment guidelines can quickly affect the market value of companies serving this large, costly area of medicine.

ascvd medical

"for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease"

Atherosclerotic cardiovascular disease (ASCVD) is the condition where fatty deposits build up inside arteries, narrowing blood flow to the heart or brain much like mineral scale clogs a pipe. It matters to investors because treatments, diagnostics, and preventive measures for ASCVD drive large markets, influence healthcare costs and insurance payouts, and affect regulatory and clinical trial outcomes that can materially change a company’s revenue prospects.

diabetic macular edema medical

"will discuss unmet clinical need in diabetic macular edema and geographic atrophy, and the opportunity"

Diabetic macular edema is an eye condition in which fluid leaks into and swells the macula, the part of the retina used for sharp, central vision, often as a complication of diabetes. For investors it matters because it drives demand for medicines, medical devices and eye-care services, influences clinical trial and regulatory outcomes, and can affect healthcare costs and revenue forecasts—think of the macula as the camera’s central lens that becomes blurred when it soaks up excess fluid.

geographic atrophy medical

"will discuss unmet clinical need in diabetic macular edema and geographic atrophy, and the opportunity"

Geographic atrophy is a progressive eye condition in which patches of light-sensing cells in the retina die, causing growing blind spots and ultimately significant central vision loss. For investors, it matters because the condition defines the market size and urgency for drugs, devices, and diagnostics — like a spreading hole in a photograph that companies aim to stop or repair — so clinical results, approvals, and reimbursement determine potential revenue and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET

Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease

Four leading academic and clinical experts will join BioAge management for presentations, followed by a live question-and-answer session

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that it will host an R&D Day webcast on Friday, May 8, 2026, from 12:30 to 2 PM Eastern Time.

The event will focus on BGE-102, the Company's potent, structurally novel, orally available NLRP3 inflammasome inhibitor with potential best-in-class attributes. Members of BioAge's leadership team will present Phase 1 clinical data and the therapeutic rationale for advancing BGE-102 in atherosclerotic cardiovascular disease (ASCVD) and retinal disease, two indication areas in which NLRP3-driven inflammation is implicated in disease pathology.

BioAge management will be joined by four leading academic and clinical experts, who will share their perspectives on NLRP3 biology and the diseases BGE-102 is being developed to treat:

• Michael Davidson, MD — Professor and Director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine, Chief Executive Officer of NewAmsterdam Pharma, and a member of BioAge's Board of Directors — will discuss the role of inflammation in ASCVD and emerging therapeutic approaches to cardiovascular risk.
• Brian Hafler, MD, PhD — Associate Professor of Ophthalmology & Visual Science at Yale School of Medicine — will discuss NLRP3-mediated inflammation in retinal disease.
• David Boyer, MD — Senior Partner at Retina-Vitreous Associates Medical Group — will discuss unmet clinical need in diabetic macular edema and geographic atrophy, and the opportunity for an oral anti-inflammatory therapy.
• Matthias Geyer, PhD — Professor of Structural Immunology and Scientific Director of the Institute of Structural Biology at the University of Bonn — will discuss the structural biology of NLRP3 inhibition and the molecular basis for BGE-102's differentiated mechanism.
  
  

The presentations will be followed by a live question-and-answer session.

Webcast Information

To view a live webcast of the event, register here. A recording of the webcast will be available in the "Events" section of BioAge's investor relations website at https://ir.bioagelabs.com/.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases including diabetic macular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers in participants with obesity and elevated inflammation. Phase 2 cardiovascular risk proof-of-concept data are anticipated in H2 2026, and Phase 1b/2a diabetic macular edema proof-of-concept data are anticipated in mid-2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

FAQ

When is BioAge's (BIOA) R&D Day webcast and what will be presented?

The webcast is on May 8, 2026 at 12:30 PM ET and runs until 2:00 PM ET. According to the company, management will present Phase 1 clinical data for BGE-102 and the therapeutic rationale for ASCVD and retinal disease.

What is BGE-102 and which indications will BioAge (BIOA) discuss on May 8, 2026?

BGE-102 is described as an orally available, potent NLRP3 inflammasome inhibitor. According to the company, the R&D Day will cover development in atherosclerotic cardiovascular disease and retinal disease.

Who are the expert presenters joining BioAge (BIOA) for the May 8, 2026 R&D Day?

Four academic and clinical experts will join management: Michael Davidson, Brian Hafler, David Boyer, and Matthias Geyer. According to the company, each will present on NLRP3 biology and disease-specific perspectives followed by live Q&A.

How can investors watch or access the BioAge (BIOA) R&D Day webcast on May 8, 2026?

Investors can view the live webcast by registering via the company's webcast link. According to the company, a recording will be posted in the Events section of BioAge's investor relations website after the event.

Will BioAge (BIOA) present clinical data at the R&D Day and what stage is that data?

Yes, management will present clinical data described as Phase 1 results for BGE-102. According to the company, the presentation will include the therapeutic rationale and implications for ASCVD and retinal disease development.